SG11202111387YA - Oligonucleotide compositions and methods of use thereof - Google Patents
Oligonucleotide compositions and methods of use thereofInfo
- Publication number
- SG11202111387YA SG11202111387YA SG11202111387YA SG11202111387YA SG11202111387YA SG 11202111387Y A SG11202111387Y A SG 11202111387YA SG 11202111387Y A SG11202111387Y A SG 11202111387YA SG 11202111387Y A SG11202111387Y A SG 11202111387YA SG 11202111387Y A SG11202111387Y A SG 11202111387YA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- oligonucleotide compositions
- oligonucleotide
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962838763P | 2019-04-25 | 2019-04-25 | |
| PCT/US2020/029959 WO2020219983A2 (en) | 2019-04-25 | 2020-04-24 | Oligonucleotide compositions and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202111387YA true SG11202111387YA (en) | 2021-11-29 |
Family
ID=72941792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202111387YA SG11202111387YA (en) | 2019-04-25 | 2020-04-24 | Oligonucleotide compositions and methods of use thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230145795A1 (en) |
| EP (1) | EP3959318A4 (en) |
| AU (1) | AU2020262485A1 (en) |
| BR (1) | BR112021021214A2 (en) |
| CA (1) | CA3137741A1 (en) |
| MX (1) | MX2021012981A (en) |
| SG (1) | SG11202111387YA (en) |
| WO (1) | WO2020219983A2 (en) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013288048A1 (en) | 2012-07-13 | 2015-01-22 | Wave Life Sciences Ltd. | Asymmetric auxiliary group |
| KR20220139425A (en) | 2012-07-13 | 2022-10-14 | 웨이브 라이프 사이언시스 리미티드 | Chiral control |
| MA43072A (en) | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
| AU2017234150B2 (en) | 2016-03-13 | 2021-09-16 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
| AU2017281497B2 (en) | 2016-06-22 | 2023-04-06 | Proqr Therapeutics Ii B.V. | Single-stranded RNA-editing oligonucleotides |
| JP7296882B2 (en) | 2016-11-23 | 2023-06-23 | ウェイブ ライフ サイエンシズ リミテッド | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
| US11597927B2 (en) | 2017-06-02 | 2023-03-07 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| WO2018223056A1 (en) | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| US11718638B2 (en) | 2017-06-21 | 2023-08-08 | Wave Life Sciences Ltd. | Compounds, compositions and methods for synthesis |
| WO2019032607A1 (en) | 2017-08-08 | 2019-02-14 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| CN111108096A (en) | 2017-09-18 | 2020-05-05 | 波涛生命科学有限公司 | Oligonucleotide preparation technology |
| EP3694530A4 (en) | 2017-10-12 | 2021-06-30 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| EP3752612A4 (en) | 2018-02-12 | 2021-11-10 | Ionis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
| KR20210018267A (en) | 2018-05-07 | 2021-02-17 | 알닐람 파마슈티칼스 인코포레이티드 | Extrahepatic delivery |
| WO2023076352A2 (en) * | 2021-10-27 | 2023-05-04 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| CA3236136A1 (en) * | 2021-10-27 | 2023-05-04 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| WO2023152371A1 (en) | 2022-02-14 | 2023-08-17 | Proqr Therapeutics Ii B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
| WO2023183556A2 (en) * | 2022-03-24 | 2023-09-28 | Amcyte Pharma, Inc. | Treatment for retinal disorders |
| WO2024013361A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Oligonucleotides for adar-mediated rna editing and use thereof |
| WO2024013360A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
| WO2024073705A1 (en) * | 2022-09-30 | 2024-04-04 | University Of Massachusetts | Ocular delivery of oligonucleotides |
| GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
| WO2024110565A1 (en) | 2022-11-24 | 2024-05-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis |
| GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
| WO2024121373A1 (en) | 2022-12-09 | 2024-06-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of cardiovascular disease |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2742136B1 (en) * | 2011-08-11 | 2017-09-27 | Ionis Pharmaceuticals, Inc. | Gapped oligomeric compounds comprising 5'-modified deoxyribonucleosides in the gap and uses thereof |
| PT3094728T (en) * | 2014-01-16 | 2022-05-19 | Wave Life Sciences Ltd | Chiral design |
| BR112017017178A2 (en) * | 2015-02-26 | 2018-04-03 | Ionis Pharmaceuticals Inc | p23h rhodopsin allele-specific modulators |
| MA43072A (en) * | 2015-07-22 | 2018-05-30 | Wave Life Sciences Ltd | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
| EP3359523A4 (en) * | 2015-10-09 | 2019-07-24 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| MA45270A (en) * | 2016-05-04 | 2017-11-09 | Wave Life Sciences Ltd | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
-
2020
- 2020-04-24 CA CA3137741A patent/CA3137741A1/en active Pending
- 2020-04-24 AU AU2020262485A patent/AU2020262485A1/en active Pending
- 2020-04-24 WO PCT/US2020/029959 patent/WO2020219983A2/en unknown
- 2020-04-24 EP EP20794544.5A patent/EP3959318A4/en active Pending
- 2020-04-24 US US17/605,997 patent/US20230145795A1/en active Pending
- 2020-04-24 MX MX2021012981A patent/MX2021012981A/en unknown
- 2020-04-24 SG SG11202111387YA patent/SG11202111387YA/en unknown
- 2020-04-24 BR BR112021021214A patent/BR112021021214A2/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020219983A2 (en) | 2020-10-29 |
| MX2021012981A (en) | 2022-01-18 |
| CA3137741A1 (en) | 2020-10-29 |
| AU2020262485A1 (en) | 2021-11-11 |
| BR112021021214A2 (en) | 2022-01-04 |
| US20230145795A1 (en) | 2023-05-11 |
| EP3959318A2 (en) | 2022-03-02 |
| EP3959318A4 (en) | 2023-10-25 |
| WO2020219983A3 (en) | 2020-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL291933A (en) | Oligonucleotide compositions and methods of use thereof | |
| SG11202111387YA (en) | Oligonucleotide compositions and methods of use thereof | |
| IL277889A (en) | Oligonucleotide compositions and methods of use thereof | |
| SG11202111386UA (en) | Oligonucleotide compositions and methods of use thereof | |
| SG11202010131QA (en) | Oligonucleotide compositions and methods of use thereof | |
| EP3965780A4 (en) | Oligonucleotide compositions and methods of use thereof | |
| EP4037695A4 (en) | Oligonucleotide compositions and methods of use thereof | |
| IL284882A (en) | Oligonucleotide compositions and methods thereof | |
| EP3630199A4 (en) | Oligonucleotide compositions and methods of use thereof | |
| EP3630788A4 (en) | Oligonucleotide compositions and methods of use thereof | |
| EP3630789A4 (en) | Oligonucleotide compositions and methods of use thereof | |
| SG11202105626TA (en) | Oligonucleotide compositions and methods thereof | |
| GB2582482B (en) | CASZ compositions and methods of use | |
| GB2582100B (en) | CAS12C Compositions and methods of use | |
| ZA201906169B (en) | Synthekine compositions and methods of use | |
| ZA202100780B (en) | Bismuth-thiol compositions and methods of use | |
| IL276135A (en) | Compositions and methods of use | |
| GB202105087D0 (en) | Microbial compositions and methods of use | |
| IL288259A (en) | Modified gapmer oligonucleotides and methods of use | |
| IL285247A (en) | Enhanced nitrate compositions and methods of use | |
| SG11202011227VA (en) | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and methods of use thereof | |
| IL282533A (en) | Oligosaccharide compositions and methods of use thereof | |
| ZA201908276B (en) | Charge-tagged nucleotides and methods of use thereof | |
| IL311625A (en) | Oligonucleotide compositions and methods thereof | |
| IL287797A (en) | Oligosaccharide compositions and methods of use |